Differential regulation of autophagy and cell viability by ceramide species

Cancer Biology and Therapy

Volumn 16, Issue 5, 2015, Pages 733-742

  Cruickshanks, Nichola ^a   Roberts, Jane L ^a   Bareford, M Danielle ^a   Tavallai, Mehrad ^a   Poklepovic, Andrew ^b   Booth, Laurence ^a   Spiegel, Sarah ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alimta; Autophagy; Ceramide; CerS2; CerS6; FTY720; Gilenya; Pemetrexed; S1P

Indexed keywords

AUTOPHAGY PROTEIN 5; BECLIN 1; CERAMIDE; CERAMIDE SYNTHASE 2; CERAMIDE SYNTHASE 6; FINGOLIMOD; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PEMETREXED; PROTEIN KINASE B; PROTEIN P53; PROTEIN P62; PROTEIN P70; RAS PROTEIN; S6 KINASE; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BRAIN CANCER; BREAST CANCER; CANCER CELL; CELL DEATH; CELL KILLING; CELL VACUOLE; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; ENZYME REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN DEPLETION; PROTEIN EXPRESSION; CELL SURVIVAL; IMMUNOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AUTOPHAGY; CELL LINE, TUMOR; CELL SURVIVAL; CERAMIDES; FINGOLIMOD HYDROCHLORIDE; HUMANS; PEMETREXED; SIGNAL TRANSDUCTION;

EID: 84943786306     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1026509     Document Type: Article

References (44)

1. Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009; 69: 5467-74; PMID: 19549896; http://dx. doi. org/10. 1158/0008-5472. CAN-08-4979.
2. Rothbart SB, Racanelli AC, Moran RG. Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res. 2010; 70: 10299-10309; PMID: 21159649; http://dx. doi. org/10. 1158/0008-5472. CAN-10-1873.
3. Jarmula A. Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs. Mini Rev Med Chem. 2010; 13: 1211-22; http://dx. doi. org/10. 2174/13895575110091211.
4. Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, Dickson R, Tudur Smith C, Davis H, Green J, et al. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess. 2010; 14 S1: 47-53.
5. Paglin S, Lee NY, Nakar C, Fitzgerald M, Plotkin J, Deuel B, Hackett N, McMahill M, Sphicas E, Lampen N, et al. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res. 2005; 65: 11061-70; PMID: 16322256; http://dx. doi. org/10. 1158/0008-5472. CAN-05-1083.
6. Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eullit P, Hubbard N, Tye G, Burow ME, et al. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Research. 2011; 71: 4955-4967; PMID: 21622715; http://dx. doi. org/10. 1158/0008-5472. CAN-11-0898.
7. Codogno P, Meijer MA. Authophagy and Signaling: Their role in cell survival and cell death. Cell Death and Differentiation. 2005; 12: 1509-1518; PMID: 16247498; http://dx. doi. org/10. 1038/sj. cdd. 4401751.
8. Ishdorj G, Li L, Gibson SB. Regulation of autophagy in hematological malignancies: role of reactive oxygen species. Leuk Lymphoma. 2012; 53: 26-33; PMID: 21749305; http://dx. doi. org/10. 3109/10428194. 2011. 604752.
9. Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J. 2012; 441: 523-40; PMID: 22187934; http://dx. doi. org/10. 1042/BJ20111451.
10. Kung CP, Budina A, Balaburski G, Bergenstock MK, Murphy M. Autophagy in tumor suppression and cancer therapy. Crit Rev Eukaryot Gene Expr. 2011; 21: 71-100; PMID: 21967333; http://dx. doi. org/10. 1615/CritRevEukarGeneExpr. v21. i1. 50.
11. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature Reviews Drug Discovery 9, 883-897; PMID: 21031003; http://dx. doi. org/10. 1038/nrd3248.
12. Brinkmann, V., Pinschewer D, Chiba K, Feng, L. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol. Sci. 2000; 21, 49-52.
13. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 2003; 554: 189-93; http://dx. doi. org/10. 1016/S0014-5793 (03)01168-2.
14. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 2002; 277, 21453-21457; PMID: 11967257; http://dx. doi. org/10. 1074/jbc. C200176200.
15. Zemann B, Kinzel B, Müller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T, Billich A. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006; 107, 1454-1458; PMID: 16223773; http://dx. doi. org/10. 1182/blood-2005-07-2628.
16. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 2004; 18, 551-553; PMID: 14715694.
17. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013; 23: 107-20; PMID: 23273921; http://dx. doi. org/10. 1016/j. ccr. 2012. 11. 013.
18. Lahiri S, Park H, Laviad EL, Lu X, Bittman R, Futerman AH. Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner. J Biol Chem. 2009; 284: 16090-8; PMID: 19357080; http://dx. doi. org/10. 1074/jbc. M807438200.
19. Liao A, Hu R, Zhao Q, Li J, Li Y, Yao K, Zhang R, Wang H, Yang W, Liu Z. Autophagy induced by FTY720 promotes apoptosis in U266 cells. Eur J Pharm Sci. 2012; 45: 600-5; PMID: 22281442; http://dx. doi. org/10. 1016/j. ejps. 2011. 12. 014.
20. Wallington-Beddoe CT, Hewson J, Bradstock KF, Bendall LJ. FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy. 2011; 7: 707-15; PMID: 21460633; http://dx. doi. org/10. 4161/auto. 7. 7. 15154.
21. Zhang N, Qi Y, Wadham C, Wang L, Warren A, Di W, Xia P. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. Autophagy. 2010; 6: 1157-67; PMID: 20935520; http://dx. doi. org/10. 4161/auto. 6. 8. 13614.
22. Cristobal I, Manso R, Rincon R, Carames C, Senin C, Borrero A, Martinez-Useros J, Rodriguez M, Zazo S, Martinez-Aguilera O, et al. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther. 2014 Apr; 13 (4): 938-47; PMID: 24448818; http://dx. doi. org/10. 1158/1535-7163. MCT-13-0150.
23. Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, Muthusamy N, Byrd JC, Cheng AL, Chen CS. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res. 2008; 68: 1204-12; PMID: 18281497; http://dx. doi. org/10. 1158/0008-5472. CAN-07-2621.
24. Ng KT, Man K, Ho JW, Sun CK, Lee TK, Zhao Y, Lo CM, Poon RT, Fan ST. Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway. Int J Oncol. 2007; 30: 375-80; PMID: 17203219.
25. Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu R, Fan ST. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis. 2004; 25: 2397-405; PMID: 15297371; http://dx. doi. org/10. 1093/carcin/bgh250.
26. - dependent pathway and impairment in ERK activity. Anticancer Res. 2003; 23: 3183-93; PMID: 12926052.
27. Bareford MD, Hamed HA, Allegood J, Cruickshanks N, Poklepovic A, Park MA, Ogretmen B, Spiegel S, Grant S, Dent P. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biol Ther. 2012; 13: 793-803; PMID: 22673740; http://dx. doi. org/10. 4161/cbt. 20562.
28. Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, Ogretmen B, Dash R, Sarkar D, Broaddus WC, et al. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res. 2010; 70: 1120-9; PMID: 20103619; http://dx. doi. org/10. 1158/0008-5472. CAN-09-4043.
29. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 2006; 66: 11954-66; PMID: 17178894; http://dx. doi. org/10. 1158/0008-5472. CAN-06-1666.
30. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 2005; 7: 164-76; PMID: 15831234; http://dx. doi. org/10. 1215/S1152851704000821.
31. Carón RW, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y, Hawkins W, Sasazuki T, Shirasawa S, Kozikowski AP, et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther. 2005; 4: 257-70; PMID: 15713897.
32. Carón RW, Yacoub A, Zhu X, Mitchell C, Han SI, Sasazuki T, Shirasawa S, Hagan MP, Grant S, Dent P. H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. Mol Cancer Ther. 2005; 4: 243-55; PMID: 15713896.
33. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009; 69: 143-50; PMID: 19117997; http://dx. doi. org/10. 1158/0008-5472. CAN-07-6656.
34. Price MM, Oskeritzian CA, Falanga YT, Harikumar KB, Allegood JC, Alvarez SE, Conrad D, Ryan JJ, Milstien S, Spiegel S. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. J Allergy Clin Immunol. 2013; 131: 501-11; PMID: 22939756; http://dx. doi. org/10. 1016/j. jaci. 2012. 07. 014.
35. Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, Yamada A, Zhao R, Milstien S, Zhou H, Spiegel S, et al. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res. 2012; 72: 726-35; PMID: 22298596; http://dx. doi. org/10. 1158/0008-5472. CAN-11-2167.
36. Jiang Q, Rao X, Kim CY, Freiser H, Zhang Q, Jiang Z, Li G. Gamma-tocotrienol induces apoptosis and autophagy in prostate cancer cells by increasing intracellular dihydrosphingosine and dihydroceramide. Int J Cancer. 2012; 130: 685-93; PMID: 21400505; http://dx. doi. org/10. 1002/ijc. 26054.
37. Shinojima N, Yokoyama T, Kondo Y, Kondo S. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy. 2007; 3: 635-7; PMID: 17786026; http://dx. doi. org/10. 4161/auto. 4916.
38. Li Y, Li S, Qin X, Hou W, Dong H, Yao L, Xiong L. The pleiotropic roles of sphingolipid signaling in autophagy. Cell Death Dis. 2014; 5: e1415; http://dx. doi. org/10. 1038/cddis. 2014. 383.
39. Pietrocola F, Izzo V, Niso-Santano M, Vacchelli E, Galluzzi L, Maiuri MC, Kroemer G. Regulation of autophagy by stress-responsive transcription factors. Semin Cancer Biol. 2013; 23: 310-22; PMID: 23726895; http://dx. doi. org/10. 1016/j. semcancer. 2013. 05. 008.
40. Hamed HA, Das SK, Sokhi UK, Park MA, Cruickshanks N, Archer K, Ogretmen B, Grant S, Sarkar D, Fisher PB, Dent P. Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells. Cancer Biol Ther. 2013; 14: 1039-49; PMID: 24025359; http://dx. doi. org/10. 4161/cbt. 26110.
41. Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, et al. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca (2C)-de novo ceramide-PP2A-reactive oxygen speciesdependent signaling pathway. Cancer Res. 2010; 70: 6313-24; PMID: 20631069; http://dx. doi. org/10. 1158/0008-5472. CAN-10-0999.
42. 2C-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Mol Cancer Ther. 2010; 9: 1378-95; PMID: 20442308; http://dx. doi. org/10. 1158/1535-7163. MCT-09-1131.
43. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013; 5: 105-21; PMID: 23180565; http://dx. doi. org/10. 1002/emmm. 201201283.
44. Sentelle RD, Senkal CE, Jiang W, Ponnusamy S, Gencer S, Selvam SP, Ramshesh VK, Peterson YK, Lemasters JJ, Szulc ZM, et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol. 2012; 8: 831-8; PMID: 22922758; http://dx. doi. org/10. 1038/nchembio. 1059.